Bank of America raises target for Galderma stock from CHF 200 to CHF 210

Bank of America raised its Galderma target from CHF 200 to CHF 210 on October 26, 2026, as reported by cash. The move followed Galderma's nine-month sales of USD 4.765 billion and its higher 2026 outlook, according to Galderma on October 22, 2026. Galderma stock was trading at EUR 203.00 at Lang & Schwarz on October 27, 2026 at 3:38 p.m. CEST.

Growth reaches every division

The nine-month sales increase was 25.1 percent at constant currency compared with the same period of 2025. Galderma raised its full-year 2026 net sales growth guidance to 22.5-23.5 percent from 19-21 percent and confirmed a Core EBITDA margin of approximately 26 percent.

Therapeutic Dermatology supplied the sharpest expansion, with sales up 64.4 percent to USD 1.347 billion in the first nine months of 2026. Nemluvio sales reached USD 735 million, while Dermatological Skincare rose 16.2 percent to USD 1.244 billion. The figures give the analyst target increase a measurable operating backdrop.

Stock stays below its yearly high

On the SIX Swiss Exchange, Galderma was trading at CHF 187.20 on October 27, 2026 at 4:35 p.m. CEST, down 1.94 percent from the prior close of CHF 190.90. The price stood 3.46 percent below the 52-week high of CHF 193.90 and 37.36 percent above the 52-week low of CHF 136.30. Trading volume was 329,301 shares.

Valuation and February 24 date

Galderma's market capitalization was CHF 43.7 billion on October 27, 2026, while its price-to-earnings ratio was 62.08. The company is also funding the planned USD 1.5 billion acquisition of ZO Skin Health with cash and bank financing. Galderma said the deal could close in the fourth quarter of 2026 or early 2027 and expects integration costs of USD 50-60 million over two years.

MarketScreener lists February 24, 2027 as the annual 2026 earnings release date. The company has also targeted a first-quarter 2027 resubmission of its U.S. application for nemolizumab, subject to regulatory feedback.

Comparison with peers

Galderma: down 1.94 percent, price-to-earnings ratio 62.08, market capitalization CHF 43.7 billion.

EssilorLuxottica (Euronext Paris, EUR): up 2.74 percent, price-to-earnings ratio 33.56, market capitalization EUR 82.6 billion.

Hermes International (Euronext Paris, EUR): down 0.51 percent, price-to-earnings ratio 29.57, market capitalization EUR 133.2 billion.

What the target increase changes

The higher CHF 210 target points to continued confidence in Galderma's sales trajectory, but the valuation remains materially above the two European peers listed above. The next evidence point is the February 24, 2027 earnings release, while the ZO Skin Health closing timetable remains a separate execution factor.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.

Market context: Market report SMI.

More news and analyses on Galderma stock